Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy

Tylan Magnusson, Luciano Costa, Smith Giri, Gayathri Ravi, Kelly Godby, Binod Dhakal, Bhagirathbhai Dholaria, Eva Medvedova, Natalie S. Callander, JoAnn Steele, Kathy Langley, Baylie Mullinax, Melissa Sentell, Stephen Horn, Candace Hill, Megan Boullion, Susan Bal

Blood (2023) 142 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2023-187343

Published: 2023

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2023-182345

Published: 2023

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Journal Articles

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Timothy Martin Schmidt, Bhagirathbhai Dholaria, Kelly N. Godby, Rebecca Silbermann, Susan Bal, Anita D'Souza, Smith Giri, James L. Omel, Parameswaran Hari, Natalie Callander, Binod Dhakal

Blood (2022) 140 (Supplement 1): 7275–7277.

https://doi.org/10.1182/blood-2022-156730

Published: 2022

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

Journal Articles

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan

Blood (2022) 140 (Supplement 1): 7284–7285.

https://doi.org/10.1182/blood-2022-159665

Published: 2022

Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2022) 140 (Supplement 1): 4834–4838.

https://doi.org/10.1182/blood-2022-162741

Published: 2022

Journal Articles

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Timothy Martin Schmidt, Rebecca Silbermann, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N. Godby, Sonia Gowda, Eva Medvedova, Natalie Callander, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10077–10078.

https://doi.org/10.1182/blood-2022-164930

Published: 2022

Journal Articles

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Smith Giri, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy Martin Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Anita D'Souza, Aric C. Hall, Pamela Hardwick, Jim Omel, Robert Frank Cornell, Natalie Callander, Parameswaran Hari, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 4431–4433.

https://doi.org/10.1182/blood-2022-160381

Published: 2022

Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 7261–7263.

https://doi.org/10.1182/blood-2022-163809

Published: 2022

Journal Articles

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Susan Bal, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari, Luciano J. Costa

Blood (2021) 138 (Supplement 1): 483.

https://doi.org/10.1182/blood-2021-145533

Published: 2021

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Susan Bal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari

Blood (2021) 138 (Supplement 1): 481.

https://doi.org/10.1182/blood-2021-145494

Published: 2021

Journal Articles

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Vasudha Sehgal, Kingston Kang, Jeremy A. Ross, L. Leanne Lash-Fleming, Yan Luo, Nizar J. Bahlis

Blood (2021) 138 (Supplement 1): 817.

https://doi.org/10.1182/blood-2021-146043

Published: 2021

Journal Articles

An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ® ) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma

Sumit Madan, Al-Ola Abdallah, Andrew J. Cowan, William I. Bensinger, Jens Hillengass, Xavier Leleu, Eva Medvedova, Caitlin Costello, Brea Lipe, Henning Schade, Rajneesh Nath, Liping Laura Sun

Blood (2021) 138 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2021-148176

Published: 2021

Journal Articles

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Nizar J. Bahlis, Jonathan L. Kaufman, Rachid Baz, Hang Quach, Shir-Jing Ho, Annette J. Vangsted, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Orlando F. Bueno, Yan Luo, Christine Mantis, Deeksha Vishwamitra, Jeremy A. Ross, Simon J Harrison

Blood (2021) 138 (Supplement 1): 1633.

https://doi.org/10.1182/blood-2021-146012

Published: 2021

Journal Articles

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

Derek Galligan, MD, Staci Williamson, MS, Jessie Myers, Rebecca W. Silbermann, MD, Eva Medvedova, MD, Levanto Schachter, DO,MS, Sarah J. Nagle, MD, Andy Chen, MDPhD, Richard T. Maziarz, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142770

Published: 2020

Journal Articles

HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Henning Schade, MD, Sumit Madan, MD, Eva Medvedova, MD, Rajneesh Nath, MD, Lisa Knapp, Bryan Lemon, PhD, Liping Laura Sun, PhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-136012

Published: 2020

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Luciano J. Costa, MD PhD, Saurabh Chhabra, MD, Kelly N. Godby, MD, Eva Medvedova, MD, Robert F. Cornell, MD MS, Aric C. Hall, MD, Rebecca W. Silbermann, MD, Racquel Innis-Shelton, MD, Binod Dhakal, MBBS, Diego DeIdiaquez, MD, Pamela Hardwick, RN, Yelak Biru, James L. Omel, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD

Blood (2019) 134 (Supplement_1): 860.

https://doi.org/10.1182/blood-2019-123170

Published: 2019

NARROW

Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ® ) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only